MedTrace Logo

A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia

NCT05702645 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 330

Last updated 2026-05-05

No results posted yet for this study

Summary

This study attempts to learn more about the health of persons with Down syndrome after treatment for acute leukemia. Children with Down syndrome are at increased risk for side effects during treatment for acute leukemia, but it is unclear of their risk for long-term effects of cancer treatment. By learning more about the factors that may contribute to chronic health conditions and long-term effects after treatment for leukemia in persons with Down syndrome, clinical practice guidelines for survivorship care can be developed to help improve their quality-of-life.

Conditions

  • B Acute Lymphoblastic Leukemia Associated With Down Syndrome
  • Down Syndrome
  • Myeloid Leukemia Associated With Down Syndrome

Interventions

PROCEDURE

Biospecimen Collection

Patients undergo saliva/buccal and blood sample collection

OTHER

Clinical Evaluation

Undergo a clinical assessment

OTHER

Neurocognitive Assessment

Undergo neurocognitive assessment

OTHER

Questionnaire Administration

Ancillary studies

OTHER

Survey Administration

Ancillary studies

Sponsors & Collaborators

  • Children's Oncology Group

    lead NETWORK

Principal Investigators

  • Maria M Gramatges · Children's Oncology Group

Eligibility

Min Age
6 Years
Max Age
39 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-30
Primary Completion
2029-06-30
Completion
2029-06-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05702645 on ClinicalTrials.gov